Novo Nordisk launches Wegovy pill in US market at significantly lower cost than injectable alternatives

Novo Nordisk has introduced the first oral formulation of its blockbuster GLP-1 weight loss medication to the United States market, marking a significant shift in the pharmaceutical landscape for obesity treatment. The pill version of Wegovy received regulatory approval from the US Food and Drug Administration just before Christmas and is now available across more than 70,000 pharmacies nationwide, including major chains such as CVS and Costco.

The Danish pharmaceutical company has priced the medication substantially below its injectable counterparts, a strategic move that accelerates competitive pressure within the rapidly expanding GLP-1 sector. Self-paying patients can purchase the starting dose of 1.5mg for USD 5 daily, equivalent to USD 149 monthly. The 4mg dose remains available at USD 149 monthly until 15 April, after which the price increases to USD 199, whilst the highest doses cost USD 299 monthly. Insured patients face copayments starting from USD 25 monthly.

This pricing structure contrasts sharply with injectable alternatives. Novo Nordisk previously retailed its Wegovy injection at USD 349 monthly for cash-paying customers, whilst broader market prices for weight-loss injections typically exceed USD 1,000 monthly. Pharmaceutical analysts have noted the oral formulation’s pricing fell below market expectations, with UBS analyst Matt Weston highlighting the competitive implications of this approach.

The pill offers distinct advantages beyond cost considerations. The needle-free administration removes a significant barrier to patient adherence and may broaden market appeal. Clinical data demonstrates approximately 17 per cent weight loss among patients maintaining consistent treatment, providing efficacy comparable to injectable formulations. Novo Nordisk estimates over 100 million Americans living with obesity represent potential demand for this medication category.

Distribution channels reflect the company’s multi-pronged market strategy. Beyond traditional pharmacy networks, Wegovy pills are available through telehealth providers including Ro, LifeMD, and Weight Watchers. Notably, the medication will also be sold through Donald Trump’s direct-to-consumer platform TrumpRx at USD 149 monthly for the starting dose, representing an unconventional distribution partnership for pharmaceutical products.

Novo Nordisk’s share price increased by more than 4 per cent following the announcement, though equity performance remains significantly depressed at 44 per cent below levels from one year prior. The company faces intensifying competition from American rival Eli Lilly, whose GLP-1 medications Mounjaro and Zepbound have captured substantial market share. Eli Lilly is developing its own oral formulation and has signalled plans to cap pricing at USD 399 monthly for cash-paying patients should regulatory approval be granted.

The Wegovy pill currently holds exclusive status as the sole GLP-1 oral medication available in the United States market. Regulatory submissions for the formulation are under review in the United Kingdom, with approval decisions expected before year-end. This expanded therapeutic option represents a critical pivot for Novo Nordisk, which issued multiple profit warnings in 2024, implemented significant workforce reductions, and restructured executive leadership amid competitive pressures within the weight-loss medication sector.